#### 1 Regional replacement of SARS-CoV-2 variant BA.1 with BA.2 as observed through 2 wastewater surveillance

3

Alexandria B. Boehm<sup>1\*</sup>, Bridgette Hughes<sup>2</sup>, Marlene K. Wolfe<sup>3</sup>, Bradley J. White<sup>2</sup>, Dorothea
 Duong<sup>2</sup>, Vikram Chan-Herur<sup>2</sup>

6

7 1. Department of Civil & Environmental Engineering, Stanford University, 473 Via Ortega,

- 8 Stanford, CA, USA, 94305
- 9 2. Verily Life Sciences, South San Francisco, CA, USA, 94080

10 3. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory

- 11 University, 1518 Clifton Rd, Atlanta, GA, USA, 30322
- 12

13 \* Corresponding author: Alexandria Boehm, Dept Civil and Environmental Engineering, Stanford

- 14 University, Stanford, California, USA, 94305, aboehm@stanford.edu, 650-724-9128
- 15

## 16 Graphical Abstract



#### 20 Abstract

- 21
- 22 An understanding of circulating SARS-CoV-2 variants can inform pandemic response, vaccine
- 23 development, disease epidemiology, and use of monoclonal antibody treatments. We developed
- 24 custom assays targeting characteristic mutations in SARS-CoV-2 variants Omicron BA.1 and
- 25 BA.2 and confirmed their sensitivity and specificity in silico and *in vitro*. We then applied these
- 26 assays to daily wastewater solids samples from eight publicly owned treatment works in the
- 27 greater Bay Area of California, USA, over four months to obtain a spatially and temporally
- 28 intensive data set. We documented regional replacement of BA.1 with BA.2 in agreement with,
- 29 and ahead of, clinical sequencing data. This study highlights the utility of wastewater
- 30 surveillance for real time tracking of SARS-CoV-2 variant circulation.
- 31 Key words: Omicron, wastewater, SARS-CoV-2, wastewater-based epidemiology
- 33 **Synopsis:** Wastewater surveillance was used to document regional emergence of SARS-CoV-
- 34 2 variant Omicron BA.2 ahead of clinical surveillance.

35

#### 36 Introduction

Knowing when a new SARS-CoV-2 variant arrives locally is of utmost importance to pandemic 37 38 response in order to ensure a rapid response to new features of the virus. In late 2021, the 39 Omicron variant emerged in South Africa and guickly spread to Europe and then North America 40 during a period of time during which Delta was the dominant circulating variant. The Omicron 41 variant resulted in a virus more transmissible and less susceptible to therapeutics and vaccines 42 than previous lineages<sup>1</sup>. Given these implications for public health, timely identification of its 43 introduction into a new community was critical. Variant identification is usually accomplished 44 through sequencing of clinical specimens, but the time between specimen collection, and the 45 return of sequencing information to public health officials is approximately two weeks. For example, outbreak.info<sup>2</sup>, a website that provides analysis and visualization of SARS-CoV-2 46 clinical sequences deposited in GISAID<sup>3,4</sup>, stresses data are unreliable and incomplete during 47 the 1-2 week window preceding the query date. 48

49

50 Wastewater represents a biological composite sample from the contributing community. It 51 contains feces, urine, sputum, mucus, blood, vomitus, and any other excretion that goes down a drain into the sewer network. Global investigations have illustrated that SARS-CoV-2 RNA 52 53 concentrations, whether measured by RT-QPCR or digital RT-PCR, or in the liquid or solid 54 phase of wastewater, correlates well with laboratory-confirmed incident COVID-19 cases in the associated sewersheds<sup>5-8</sup>. A number of studies have illustrated that circulating or novel variants 55 can be identified in wastewater using RT-PCR assays that target a characteristic variant 56 mutation<sup>9–11</sup> and by sequencing SARS-CoV-2<sup>12</sup>. We previously developed targeted RT-PCR 57 58 assays for characteristic mutations in Alpha, Mu, Lambda, Delta, and Omicron BA.1, and 59 showed that the concentrations of these mutations, normalized by a pan-SARS-CoV-2 N gene target is strongly correlated to the fraction of clinical specimens classified as the associated 60 variant<sup>10,13</sup> at two publicly owned treatment works (POTWs). Here, we extend that previous work 61

62	by developing and testing two new assays, one that targets characteristic mutations in the BA.2
63	sublineage of Omicron and another that targets a set of mutations present in both BA.1 and
64	BA.2, and then applying them to wastewater samples collected daily at eight POTW in the
65	greater Bay Area, California, USA. Results presented here were available publicly within 24
66	hours of sample collection via our website (wbe.stanford.edu), and these data allowed us to
67	observe near real-time regional replacement of BA.1 with BA.2.

68

#### 69 Materials and Methods

70

71 Characteristic spike mutation assay development. Digital RT-PCR assays were designed to 72 target the BA.2 characteristic mutation LPPA24S (a 9 bp deletion), and a region of 5 adjacent 73 SNPs common to BA.1 and BA.2 (S477N,T478K,Q493R,Q498R,Y505H, hereafter S:477-505). 74 The del143-145 assay targeting a mutation present in BA.1 was developed in a similar manner described elsewhere<sup>10</sup>. According to sequences deposited in GISAID and accessed via 75 76 outbreak.info (accessed 16 April 2022), the LPPA24S mutation is present in 92% of BA.2 77 genomes, including sublineages, (hereafter BA.2\*) and 0.003% of BA.1 genomes, including sublineages, (hereafter BA.1\*) globally whereas the del143-145 mutation is present in 93% 78 79 BA.1\* and 0% BA.2\* genomes, globally (Table S1). Assays were developed in silico using 80 Primer3Plus (https://primer3plus.com/) (Table S2).

81

Primers and probe sequences (Table 1) were screened for specificity *in silico* using NCBI
BLAST, and then tested *in vitro* against various respiratory viruses and gRNA from wild-type
(WT) SARS-CoV-2 and its variants (see SI). Viral RNA was used undiluted as template in digital
droplet RT-PCR with mutation primer and probes. The concentration of gRNA used for in vitro
specificity testing was approximately 275 copies per well.

88	The sensitivity and specificity of the mutation assays were further tested by diluting target			
89	variant gRNA (Table S1) in no (0 copies), low (100 copies), and high (10,000 copies)			
90	background of WT SARS-CoV-2 gRNA.			
91				
92	Wastewater samples. Eight POTWs serving populations of the Greater Bay Area and			
93	Sacramento, California, USA were included in the study. They serve between 66,000 and 1.5			
94	million people; further descriptions are elsewhere. <sup>14</sup>			
95				
96	$50  \square mL$ of settled solids was collected each day from each POTW between 1 January 2022 a			
97	12 or 13 April 2022, during the period of time when Omicron BA.2 emerged in the region.			
98	Detailed sample collection methods are provided elsewhere <sup>14</sup> and in the SI. Samples were			
99	immediately stored at 4°C and transported to the laboratory by a courier service where			
100	processing began within $6\Box h$ of collection. Between 94 and 103 samples from each POTW			
101	were included in the analysis (total of 810).			
102				
103	RNA was extracted from 10 replicate aliquots of each dewatered settled solids sample and PCR			
104	inhibitors were removed <sup>14</sup> (see SI). RNA was processed immediately to measure concentrations			
105	of the N gene of SARS-CoV-2, the BA.1* characteristic mutation del143-145 <sup>10</sup> , the BA.2*			
106	characteristic mutation (LPPA24S), pepper mild mottle virus (PMMoV), and bovine coronavirus			
107	(BCoV) recovery using digital droplet RT-PCR methods <sup>14,15</sup> . The N gene target is present in all			
108	variants and is a pan-SARS-CoV-2 gene target. PMMoV is highly abundant in human stool and			
109	wastewater globally <sup>16,17</sup> and is used as an internal recovery for the wastewater samples <sup>18</sup> .			
110	BCoV was spiked into the samples and used as an additional recovery control; all samples were			
111	required to have greater than 10% BCoV recovery. RNA extraction and PCR negative and			
112	positive controls were included to ensure no contamination. Extracted RNA samples from one			
113	POTW (SJ) were then stored at -80°C between 1 and 7 days before they were analyzed for			

114	S:477-505 and the N gene. Each of the 10 replicate RNA extracts was run in its own well, and		
115	the 10 wells were merged for analysis. Wastewater data are available publicly at the Stanford		
116	Digital Repository (https://doi.org/10.25740/cf848zx9249); results below are reported as		
117	suggested in the EMMI guidelines <sup>19</sup> .		
118			
119	ddRT-PCR. The ddRT-PCR methods applied to wastewater solids to measure PMMoV and		
120	BCoV are provided in detail elsewhere <sup>14</sup> . The N gene and del143-145 mutation were		
121	multiplexed along with an S gene assay (not reported herein). LPPA24S mutation was		
122	multiplexed in an assay along with an influenza A and RSV N gene target (only LPPA24S		
123	reported herein). The S:477-505 mutation was multiplexed with the N gene and a characteristic		
124	mutation in Delta (not reported). Each 96-well PCR plate of wastewater samples included PCR		
125	and extraction positive and negative controls. Additional details of the PCR methods are		
126	provided in the SI.		
127			
128	QuantaSoft™ Analysis Pro Software (Bio-Rad, version 1.0.596) was used for thresholding. In		
129	order for a sample to be recorded as positive, it had to have at least three positive droplets. For		
130	the wastewater solid samples, three positive droplets across ten merged wells corresponds to a		
131	concentration between ~500-1000 copies per g (cp/g); the range in values is a result of the		
132	range in the equivalent mass of dry solids added to the wells.		

133

Concentrations of RNA targets were converted to concentrations per dry weight of solids in units of copies/g dry weight using dimensional analysis. Dry weight of dewatered solids was determined by oven drying<sup>20</sup>. The total error is reported as standard deviations and includes the errors associated with the Poisson distribution and the variability among the 10 replicates.

138

139	Variants present in regional clinical specimens. The 7-d, centered, rolling average		
140	proportion of clinical specimens sequenced from California classified as Omicon BA.1* and		
141	BA.2* as a function of specimen collection data were acquired from GISAID <sup>3,4</sup> on 21 April 2022.		
142			
143	Statistics. We normalized mutation concentrations by N gene concentrations to represent the		
144	fraction of total SARS-CoV-2 RNA (represented by the N gene assay target which is conserved		
145	across variants) that comes from the variant; hereafter referred to as relative mutation		
146	concentration. We used Kendall's tau to test for associations between the 5-d trimmed		
147	smoothed average relative concentrations and the proportion of clinical specimens assigned to		
148	the corresponding variants as the two variables were not normally distributed (Shaprio Wilk test,		
149	p<0.05 for all). The daily measured relative concentration was matched to the 7-d, centered,		
150	rolling average fraction of clinical specimens classified as the associated variant obtained from		
151	GISAID. All analysis was carried in R Studio version 1.4.1106.		
152			
153			
154	Results and Discussion		
155	Variant mutation assay specificity. In silico analysis indicated no cross reactivity between		
156	LPPA24S (targeting BA.2*) and S:477-505 (targeting BA.1* and BA.2*) assays and deposited		
157	sequences in NCBI. When challenged against a respiratory virus panel and various non-target		
158	SARS-CoV-2 variant gRNA no cross reactivity was observed; the assays amplified gRNA from		
159	BA.2, and BA.1 and BA.2, respectively. Positive controls and NTCs run on sample plates were		
160	positive and negative. When target gRNA was diluted into a background of low and high non-		
161	target gRNA from WT SARS-CoV-2; measurements were similar when there was no, low, or		
162	high background gRNA (Figure S1). Results indicate the new mutation assays are specific and		

- 163 sensitive. Wolfe et al.<sup>10</sup> showed the del143-145 (targeting BA.1) assay was sensitive and
- 164 specific.

165

Variant RNA concentrations in wastewater solids. All positive and negative controls were
positive and negative, respectively, indicating assays performed well and without contamination.
BCoV recoveries were higher than 10% and PMMoV concentrations within the expected range
for the POTW suggesting an efficient and acceptable recovery of RNA during RNA extraction
(Figure S2).

171

172 Across all eight POTWs a common pattern in N, del143-145, and LPPA24S concentrations is 173 observed. Between 1 Jan and late Feb to mid-March 2022, N and del143-145 concentrations are approximately the same, and both decrease from  $10^6$  cp/g to  $10^4$  cp/g (Figure 1). The two 174 175 order of magnitude decrease is coincident with a decline in laboratory-confirmed incident 176 COVID-19 cases in the sewersheds after the winter Omicron surge in the region (case data not 177 shown). In late Feb to mid-March until mid-April, both N and LPPA24S concentrations increase from  $10^3$  cp/g to  $10^5$  cp/g, while del143-145 concentrations decrease from  $10^4$  cp/g to  $10^2$  cp/g 178 179 or non-detect. LPPA24S concentrations are similar to those of N at the POTWs during that 180 same time period.

181

182 The ratios del143-145/N and LPPA24S/N describe the concentrations of the mutations in 183 relation to a conserved gene target. As a mutation's relative concentration approaches 1, it 184 suggests that the variant associated with the mutation may be dominant in the wastewater. 185 Del143-145 relative concentration was a maximum and close to 1 at most POTWs at the 186 beginning of the time series (1 January 2022) and then fell to nearly 0 by mid-April 2022 (Figure 187 2). At the same time, LPPA24S relative concentration increased from 0 when it was first 188 measured to near 1 at all POTWs. Depending on POTW, the date on which the LPPA24S 189 relative concentration surpassed that of del143-145 ranged from 26 February to 19 March 190 (Table S3). This date was earliest (26 Feb) at Ocean, located in San Francisco, and latest at Gil

191	and Sac; the date is positively correlated with the distance from Ocean (r =0.9, p<0.05, n=8)
192	suggesting a spatial pattern in BA.2* emergence. Regional replacement of BA.1* with BA.2*
193	appears to be complete at all POTWs by the end of the times series as the del143-145 relative
194	concentrations are close to 0 and LPPA24S relative concentrations approach 1. At times,
195	relative concentrations may exceed 1; this may be due to variability in the performance of the
196	digital RT-PCR assays. It is important to note that the relative concentrations do not incorporate
197	measurement error of the numerator or denominator.
198	

199 At SJ, we measured the concentration of an additional set of adjacent mutations present in both

200 BA.1 and BA.2 (S:477-505) (Figure 1). S:477-505 concentrations agree well with the N

201 concentrations during a period of time when BA.1\* was dominant (prior to mid-March) and when

202 BA.2\* was dominant (thereafter).

203

204 del143-145 and LPPA24S relative concentrations at each POTW are positively and significantly 205 correlated with the fraction of clinical cases in California assigned as BA.1\* and BA.2\*, 206 respectively (Table S4). Tau between relative del143-145 concentrations and proportion of 207 cases assigned as BA.1\* ranged from 0.51 at Gil to 0.81 at SAC (median tau = 0.68, all  $p < 10^{-7}$ , 208 n = 94-103). Tau between relative LPPA24S concentrations and proportion of cases assigned as BA.2\* ranged from 0.67 at Gil to 0.90 at SAC (median tau = 0.75, all  $p<10^{-5}$ , n = 58-62). Tau 209 210 values were similar when calculated using raw relative concentrations (see SI). State level 211 clinical data suggest proportion of cases caused by BA.2\* exceeds that of BA.1\* after 21 March 212 (Figure 3), later than any wastewater suggests this occurred regionally. Ideally, these analyses 213 should be carried out using data on clinical variants in the sewersheds of the eight POTWs, but 214 such data is not readily available, so we had to rely on state-level data.

216 State-level clinical sample sequencing data on variant occurrence is typically 1-2 weeks delayed owing to the time required for laboratory processing and reporting. In addition, there can be 217 218 large uncertainties in the proportion estimates preceding the data for which the most recent data 219 are available. This is illustrated in Figure 3 where we highlight the approximate time period for 220 which data were incomplete on 14 April 2022, when wastewater measurements for the last date 221 in our data series (12 or 13 April 2022) were available publicly on our website 222 (wbe.stanford.edu). During this same time period, wastewater data suggest BA.2\* is near 100% 223 and BA.1\* is near 0%, which a week later (when data were downloaded from GISAID on 21 224 April 2022) was confirmed by clinical sequencing data. This highlights an important advantage 225 of using wastewater surveillance for variant tracking. 226 227 Real-time estimates of variant abundance with high spatial resolution, such as those from 228 wastewater surveillance, could allow clinicians and regulators to identify the most effective 229 treatment for a particular community. The monoclonal antibody therapy sotrovimab provides a 230 recent and practical example. Sotrovimab was granted emergency use authorization by the US 231 FDA for treatment of infection by variants including BA.1, but not BA.2. As BA.2 took over, its 232 use was discontinued by multi-state HHS region blocks, informed by clinical sequencing data. 233 While sotrovimab was allowed for use in California until March 30, ourdata suggest BA.2 234 became the dominant variant in the Bay Area weeks prior, but before BA.2 had taken over all of 235 California and HHS region 9. Real-time wastewater variant estimates could have allowed the 236 drug's use to be targeted spatially and temporally to maximize effectiveness. 237 238 Acknowledgements. This work is supported by the CDC Foundation. Numerous people

contributed to sample collection and case data acquisition, including Srividhya Ramamoorthy
(Sac), Michael Cook (Sac), Ursula Bigler (Sac), James Noss (Sac), Lisa C. Thompson (Sac),
Payak Sarkar (SJ), Noel Enoki (SJ), and Amy Wong (SJ), Lily Chan (Ocean), the Oceanside

242	plant operations personnel, Karin North (PA), Armando Guizar (PA), Saeid Vaziry (Gil), Chris		
243	Vasquez (Gil), Alo Kauravlla (Sun), Maria Gawat (SVCW), Tiffany Ishaya (SVCW), and Jeron		
244	Miller (Dav). This study was performed on the ancestral and unceded lands of the Muwekma		
245	Ohlone people. We pay our respects to them and their Elders, past and present, and are		
246	grateful for the opportunity to live and work here. The graphic abstract was made using		
247	Biorender (biorender.com).		
248			
249	Supporting Information. Additional methods, Tables S1-S5, Figures S1-S3. This paper has		
250	been previously submitted to medRxiv, a preprint server for Health Sciences. The preprint ca		
251	be cited as: XXXX (to be provided).		
252			
253	Competing Interests. BH, DD, VC-H and BW are employees of Verily Life Sciences.		

#### 255 256 References Viana, R.; Moyo, S.; Amoako, D. G.; Tegally, H.; Scheepers, C.; Althaus, C. L.; Anyaneji, 257 (1) 258 U. J.; Bester, P. A.; Boni, M. F.; Chand, M.; Choga, W. T.; Colguhoun, R.; Davids, M.; 259 Deforche, K.; Doolabh, D.; du Plessis, L.; Engelbrecht, S.; Everatt, J.; Giandhari, J.; 260 Giovanetti, M.; Hardie, D.; Hill, V.; Hsiao, N.-Y.; Iranzadeh, A.; Ismail, A.; Joseph, C.; 261 Joseph, R.; Koopile, L.; Kosakovsky Pond, S. L.; Kraemer, M. U. G.; Kuate-Lere, L.; 262 Laguda-Akingba, O.; Lesetedi-Mafoko, O.; Lessells, R. J.; Lockman, S.; Lucaci, A. G.; 263 Maharaj, A.; Mahlangu, B.; Maponga, T.; Mahlakwane, K.; Makatini, Z.; Marais, G.; Maruapula, D.; Masupu, K.; Matshaba, M.; Mayaphi, S.; Mbhele, N.; Mbulawa, M. B.; 264 265 Mendes, A.; Mlisana, K.; Mnguni, A.; Mohale, T.; Moir, M.; Moruisi, K.; Mosepele, M.; 266 Motsatsi, G.; Motswaledi, M. S.; Mphoyakgosi, T.; Msomi, N.; Mwangi, P. N.; Naidoo, Y.; 267 Ntuli, N.; Nyaga, M.; Olubayo, L.; Pillay, S.; Radibe, B.; Ramphal, Y.; Ramphal, U.; San, 268 J. E.; Scott, L.; Shapiro, R.; Singh, L.; Smith-Lawrence, P.; Stevens, W.; Strydom, A.; Subramonev, K.: Tebeila, N.: Tshiabuila, D.: Tsui, J.: van Wvk, S.: Weaver, S.: Wibmer, 269 270 C. K.; Wilkinson, E.; Wolter, N.; Zarebski, A. E.; Zuze, B.; Goedhals, D.; Preiser, W.; 271 Treurnicht, F.; Venter, M.; Williamson, C.; Pybus, O. G.; Bhiman, J.; Glass, A.; Martin, D. 272 P.; Rambaut, A.; Gaseitsiwe, S.; von Gottberg, A.; de Oliveira, T. Rapid Epidemic 273 Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa. Nature 2022, 603 274 (7902), 679-686. https://doi.org/10.1038/s41586-022-04411-y. 275 Mullen, J. L.; Tsueng, G.; Latif, A. A.; Alkuzweny, M.; Cano, M.; Haag, E.; Zhou, J.; Zeller, (2) 276 M.; Hufbauer, E.; Matteson, N.; Andersen, K. G.; Wu, C.; Su, A. I.; Gangavarapu, K.; 277 Hughes, L. D. https://outbreak.info/. 278 Elbe, S.; Buckland-Merrett, G. Data, Disease and Diplomacy: GISAID's Innovative (3) 279 Contribution to Global Health. *Global Challenges* **2017**, *1* (1), 33–46. 280 https://doi.org/10.1002/gch2.1018. 281 (4) Shu, Y.; McCauley, J. GISAID: Global Initiative on Sharing All Influenza Data – from 282 Vision to Reality. Eurosurveillance 2017, 22 (13). https://doi.org/10.2807/1560-283 7917.ES.2017.22.13.30494. Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-284 (5) 285 Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.; Weinberger, D. 286 M.; Omer, S. B. SARS-CoV-2 RNA Concentrations in Primary Municipal Sewage Sludge 287 as a Leading Indicator of COVID-19 Outbreak Dynamics. Nature Biotechnology 2020, 38, 288 1164–1167. 289 Feng, S.; Roquet, A.; McClary-Gutierrez, J. S.; Newton, R. J.; Kloczko, N.; Meiman, J. G.; (6) 290 McLellan, S. L. Evaluation of Sampling, Analysis, and Normalization Methods for SARS-291 CoV-2 Concentrations in Wastewater to Assess COVID-19 Burdens in Wisconsin 292 Communities. ACS ES&T Water 2021, 1 (8), 1955–1965. 293 https://doi.org/10.1021/acsestwater.1c00160. 294 Kim, S.; Kennedy, L. C.; Wolfe, M. K.; Criddle, C. S.; Duong, D. H.; Topol, A.; White, B. (7) 295 J.; Kantor, R. S.; Nelson, K. L.; Steele, J. A.; Langlois, K.; Griffith, J. F.; Zimmer-Faust, A. G.; McLellan, S. L.; Schussman, M. K.; Ammerman, M.; Wigginton, K. R.; Bakker, K. M.; 296 297 Boehm, A. B. SARS-CoV-2 RNA Is Enriched by Orders of Magnitude in Primary Settled 298 Solids Relative to Liquid Wastewater at Publicly Owned Treatment Works. Environ. Sci.: 299 Water Res. Technol. 2022. https://doi.org/10.1039/D1EW00826A. 300 Fernandez-Cassi, X.; Scheidegger, A.; Bänziger, C.; Cariti, F.; Corzon, A. T.; (8) 301 Ganesanandamoorthy, P.; Lemaitre, J. C.; Ort, C.; Julian, T. R.; Kohn, T. Wastewater 302 Monitoring Outperforms Case Numbers as a Tool to Track COVID-19 Incidence 303 Dynamics When Test Positivity Rates Are High. *Water Research* **2021**, 117252. 304 https://doi.org/10.1016/j.watres.2021.117252. 305 Lee, W. L.; Imakaev, M.; Armas, F.; McElroy, K. A.; Gu, X.; Duvallet, C.; Chandra, F.; (9)

- Chen, H.; Leifels, M.; Mendola, S.; Floyd-O'Sullivan, R.; Powell, M. M.; Wilson, S. T.;
  Berge, K. L. J.; Lim, C. Y. J.; Wu, F.; Xiao, A.; Moniz, K.; Ghaeli, N.; Matus, M.;
  Thompson, J.; Alm, E. J. Quantitative SARS-CoV-2 Alpha Variant B.1.1.7 Tracking in
  Wastewater by Allele-Specific RT-QPCR. *Environ. Sci. Technol. Lett.* 2021, *8* (8), 675–
  682. https://doi.org/10.1021/acs.estlett.1c00375.
- (10) Wolfe, M. K.; Hughes, B.; Duong, D.; Chan-Herur, V.; Wigginton, W. K.; White, B. J.;
  Boehm, A. B. Detection of SARS-CoV-2 Variants Mu, Beta, Gamma, Lambda, Delta,
  Alpha, and Omicron in Wastewater Settled Solids Using Mutation-Specific Assays Is
  Associated with Regional Detection of Variants in Clinical Samples. *Applied and Environmental Microbiology 0* (0), e00045-22. https://doi.org/10.1128/aem.00045-22.
- (11) Yaniv, K.; Ozer, E.; Kushmaro, A. SARS-CoV-2 Variants of Concern, Gamma (P.1) and
  Delta (B.1.617), Sensitive Detection and Quantification in Wastewater Employing Direct
  RT-QPCR. *medRxiv* 2021, 2021.07.14.21260495.
- 319 https://doi.org/10.1101/2021.07.14.21260495.
- (12) Crits-Christoph Alexander; Kantor Rose S.; Olm Matthew R.; Whitney Oscar N.; AlShayeb Basem; Lou Yue Clare; Flamholz Avi; Kennedy Lauren C.; Greenwald Hannah;
  Hinkle Adrian; Hetzel Jonathan; Spitzer Sara; Koble Jeffery; Tan Asako; Hyde Fred;
  Schroth Gary; Kuersten Scott; Banfield Jillian F.; Nelson Kara L.; Pettigrew Melinda M.
  Genome Sequencing of Sewage Detects Regionally Prevalent SARS-CoV-2 Variants. *mBio 12* (1), e02703-20. https://doi.org/10.1128/mBio.02703-20.
- Yu, A.; Hughes, B.; Wolfe, M.; Leon, T.; Duong, D.; Rabe, A.; Kennedy, L.; Ravuri, S.;
   White, B.; Wigginton, K. R.; Boehm, A.; Vugia, D. Estimating Relative Abundance of Two
   SARS-CoV-2 Variants through Wastewater Surveillance at Two Large Metropolitan Sites.
   *Emerging Infect. Dis.* 2022, 28 (5), 940–947.
- Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.;
  Balliet, M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight
  Publicly Owned Treatment Works in Northern California Shows Strong Association with COVID-19 Incidence. *mSystems* 2021, 0 (0), e00829-21.
  https://doi.org/10.1128/mSystems.00829-21.
- (15) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput SARS-COV-2,
   PMMOV, and BCoV Quantification in Settled Solids Using Digital RT-PCR. *protocols.io* 2021.
- Kitajima, M.; Sassi, H. P.; Torrey, J. R. Pepper Mild Mottle Virus as a Water Quality
  Indicator. *npj Clean Water* **2018**, *1* (1), 19. https://doi.org/10.1038/s41545-018-0019-5.
- (17) Symonds, E. M.; Nguyen, K. H.; Harwood, V. J.; Breitbart, M. Pepper Mild Mottle Virus: A
  Plant Pathogen with a Greater Purpose in (Waste)Water Treatment Development and
  Public Health Management. *Water Research* 2018, 144, 1–12.
  https://doi.org/10.1016/j.watres.2018.06.066.
- 345 McClary-Gutierrez, J. S.; Aanderud, Z. T.; Al-faliti, M.; Duvallet, C.; Gonzalez, R.; (18) Guzman, J.; Holm, R. H.; Jahne, M. A.; Kantor, R. S.; Katsivelis, P.; Kuhn, K. G.; Langan, 346 347 L. M.; Mansfeldt, C.; McLellan, S. L.; Mendoza Grijalva, L. M.; Murnane, K. S.; Naughton, 348 C. C.; Packman, A. I.; Paraskevopoulos, S.; Radniecki, T. S.; Roman, F. A.; Shrestha, A.; Stadler, L. B.; Steele, J. A.; Swalla, B. M.; Vikesland, P.; Wartell, B.; Wilusz, C. J.; Wong, 349 350 J. C. C.; Boehm, A. B.; Halden, R. U.; Bibby, K.; Delgado Vela, J. Standardizing Data 351 Reporting in the Research Community to Enhance the Utility of Open Data for SARS-352 CoV-2 Wastewater Surveillance. Environ. Sci.: Water Res. Technol. 2021, 7 (9), 1545-353 1551. https://doi.org/10.1039/D1EW00235J.
- Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T.
   The Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and
   DPCR Quality and Reporting for Environmental Microbiology. *Environ. Sci. Technol.*

### 357 **2021**, *55* (15), 10210–10223. https://doi.org/10.1021/acs.est.1c01767.

Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput Pre-Analytical
 Processing of Wastewater Settled Solids for SARS-CoV-2 RNA Analyses. *protocols.io* 2021.

- 361
- 362



Mutations		Sequence
LPPA24S	Forward	GCCACTAGTCTCTAGTCAGTGTG
	Reverse	TGTCAGGGTAATAAACACCACGT
	Probe	CAGAACTCAATCATACACTAATTCTTTCAC (5' FAM or HEX/ZEN/3' IBFQ)
S·177-505		
0.477-000	Forward	CTATCAGGCCGGTAACAAAC
	Reverse	ACTACTCTGTATGGTTGGTGAC
	Probe	CCTTTACGATCATATRGTTTCCGACCC 5' FAM or HEX/ZEN/3' IBFQ)

Table 1. Primers and probes for new mutation assays. Primers and probes for other assays that
 are previously published are in Table S5. Information on the fluorescent molecule and
 quenchers used for the probes are provided in parentheses after their sequence. FAM, 6 fluorescein amidite; HEX, hexachloro-fluorescein; ZEN, a proprietary internal quencher from
 IDT; IBFQ, Iowa Black FQ.



# 376

Figure 1. Concentrations of N, del143-145, LPPA24S, and S:477-505 at 8 POTWs in the study (name indicated in corner). Error bars are 68% confidence intervals that include error from variation among 10 replicate wells, and Poisson error ("total error" as reported by the instrument). If error bars cannot be seen, they are smaller than the symbol.



382 Figure 2. Relative concentrations of del143-145 and LPPA24S (their concentrations normalized by the N gene) at 8 POTWs in the study (name indicated in corner). Markers are raw ratio values. Lines represent 5-day trimmed moving averages. 



389 390 Figure 3. Percentage of clinical cases in California classified as indicated BA.1\* and BA.2\* as a 391 function of specimen collection date; data represent 7-d moving average as acquired from 392 GISAID. Data available through 13 April when downloaded from GISAID on 21 April 2022. Gray 393 area represents the time period for which data were incomplete on 14 April 2022, when wastewater measurements for the last date in our data series (12 or 13 April 2022) were 394 395 available.